Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

INTRODUCTION: Optimal antithrombotic strategy following transcatheter aortic valve replacement (TAVR) is still unknown. We hypothesised that the direct factor Xa inhibitor edoxaban can potentially prevent subclinical leaflet thrombosis and cerebral embolisation compared with conventional dual antipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hanbit, Kang, Do-Yoon, Ahn, Jung-Min, Kim, Kyung Won, Wong, Anthony Y T, Lam, Simon C C, Yin, Wei-Hsian, Wei, Jeng, Lee, Yung-Tsai, Kao, Hsien-Li, Lin, Mao-Shin, Ko, Tsung-Yu, Kim, Won-Jang, Kang, Se Hun, Ko, Euihong, Kim, Dae-Hee, Koo, Hyun Jung, Yang, Dong Hyun, Kang, Joon-Won, Jung, Seung Chai, Lee, Jae-Hong, Yun, Sung-Cheol, Park, Seung-Jung, Park, Duk-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786793/
https://www.ncbi.nlm.nih.gov/pubmed/33402409
http://dx.doi.org/10.1136/bmjopen-2020-042587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786793/
https://www.ncbi.nlm.nih.gov/pubmed/33402409
http://dx.doi.org/10.1136/bmjopen-2020-042587

Ejemplares similares